Nathan L. Mata, who serves as Chief Scientific Officer at BELITE BIO, INC (NASDAQ:BLTE), sold a total of 1,000 American depositary shares on April 16, 2026. The aggregate proceeds from those sales were about $160,380, with trade prices reported between $158.16 and $164.22 per ADS.
The sales were executed under a Rule 10b5-1 trading plan that Mr. Mata adopted on December 10, 2025. Each American depositary share represents one ordinary share of the company. After the April 16 transactions, Mr. Mata directly holds 14,666 ADS in Belite Bio.
Belite Bio's stock is trading at $165.43, a level that reflects a 193% gain over the past 12 months. The insider sales occurred at a range slightly below the current quoted price.
Financial health and profitability
According to available analysis, the company holds a "GOOD" financial health score while remaining unprofitable on an earnings-per-share basis, with EPS reported at -$2.31. A detailed Pro Research Report covering Belite Bio is noted as available among a suite of in-depth company reports for investors seeking further data.
Regulatory progress and analyst reactions
Belite Bio has been the subject of analyst attention following developments tied to its investigational therapy, tinlarebant. The company intends to submit a New Drug Application to the U.S. Food and Drug Administration for tinlarebant, citing positive results from the Phase 3 DRAGON trial in adolescent Stargardt disease.
In response to the trial outcome, H.C. Wainwright reiterated a Buy rating and raised its price target to $200. Benchmark increased its target to $217, emphasizing that the DRAGON trial met its primary efficacy endpoint with a reported 35.7% reduction in the rate of macular lesion growth. Mizuho retained an Outperform rating and updated its expectation for the NDA submission to the second quarter of 2026, with a possible approval in early 2027.
Cash runway and commercialization planning
Benchmark's review indicates Belite Bio concluded the year with $353 million in cash and $420 million in investments, a combined position described as providing more than two years of financial runway. The company has outlined planned allocations to support a commercial launch of tinlarebant, including $150 million earmarked for research and development and $250 million for sales and marketing over the next four years.
The sequence of insider sales, the announced 10b5-1 plan, the company's financial profile, and its regulatory roadmap for tinlarebant together form the current set of publicly disclosed developments investors and market participants can evaluate. No additional assertions or projections beyond those reported have been included.